HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Distressing’ Substantiation Trends Tighten FTC Supplement Claim Enforcement

This article was originally published in The Tan Sheet

Executive Summary

FTC tightens requirements for claims substantiation due to fraud in studies and peer reviews, but its changes are not “monumental,” says Division of Advertising Practice official Richard Cleland. FTC likely will find it necessary to ask more supplement or nutritional product firms to conduct RCTs to support marketing claims, he adds.

You may also be interested in...



FTC Requests Drug Claim Support For Bayer Probiotic Supplement

On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.

Arcaea Resurrects Extinct Flowers With First Fragrances Under Future Society Brand; Cosmetics News

Coty and English footballer David Beckham announce a collection of eau de parfums rolling out to US retailers nationwide in January following a debut in JCPenney. Arcaea introduces biotech-based scents capturing the essence of extinct flowers, and Procter & Gamble’s Mielle hair-care brand launches its first ad campaign. More product launch and marketing news.

FDA’s OTC Monograph User Fees Are Existential Threat To Small Contract Manufacturers, Cosmetics Brands

OMUFA reauthorization should include small business considerations for the US FDA’s OTC Monograph Drug User Fee Program, which established in 2020 a ‘one-size-fits-all’ facility and monograph order request user fee system which could lead to more contract manufacturer exits, a manufacturing bottleneck for OTC cosmetic products, and fewer product choices, says IBA.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel